• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharmather Hldgs Ltd (OP: PHRRF )

0.1600 +0.0075 (+4.92%)
Streaming Delayed Price Updated: 9:49 AM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pharmather Hldgs Ltd

< Previous 1 2 Next >
PharmaTher Announces Update on FDA New Drug Application for Ketamine
November 26, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
November 19, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application
November 13, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
November 12, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application
October 23, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Update on FDA New Drug Application for Ketamine
September 04, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)
August 19, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
May 10, 2024
The FDA Assigned Goal Date is October 29, 2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 01, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 18, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
April 16, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
April 02, 2024
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
February 21, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
February 12, 2024
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Provides Update for Expected FDA Approval of Ketamine
January 10, 2024
Assigned FDA approval goal date of April 29, 2024, is still on track 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
September 27, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
September 06, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
July 18, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
June 27, 2023
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
June 20, 2023
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Provides Corporate Update
June 12, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
May 02, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech
April 03, 2023
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
March 29, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
February 07, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From Revive Therapeutics Ltd.
Via GlobeNewswire
PharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome
February 02, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
February 01, 2023
From PharmaTher Holdings Ltd.
Via GlobeNewswire
< Previous 1 2 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap